ecrin-mdr-crcClinical2013Neoplasm MetastasisMetastatic DiseaseColorectal NeoplasmsCáncer Colorrectal MetastásicoMetastatic colorectal cancerColorectal cancer stage IVMetastatic Colorectal CancerColorectal Cancer Stage IvNeoplasm MetastasisMetastatic DiseaseColorectal NeoplasmsCáncer Colorrectal MetastásicoInterventionalhttps://newmdr.ecrin.org/Study/2146473Spain6RegorafenibFrail and unfit patientMetastatic colorectal cancerECRIN MDRCompletedfalseRegorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal CancerThe purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)2013-06-152146473NCT018753802013-000236-94